Anja Lorch
A5042221345- Prostate Cancer Treatment and Research
- PARP inhibition in cancer therapy
- Bladder and Urothelial Cancer Treatments
- Testicular diseases and treatments
- Cancer Treatment and Pharmacology
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Sarcoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Urologic and reproductive health conditions
- Multiple Myeloma Research and Treatments
- Radiopharmaceutical Chemistry and Applications
- Urological Disorders and Treatments
- Cancer Genomics and Diagnostics
- Palliative Care and End-of-Life Issues
- Neuroblastoma Research and Treatments
- Grief, Bereavement, and Mental Health
- Esophageal Cancer Research and Treatment
- Occupational and environmental lung diseases
- Pancreatic and Hepatic Oncology Research
- Neutropenia and Cancer Infections
- Economic and Financial Impacts of Cancer
- Ovarian cancer diagnosis and treatment
- Cancer, Lipids, and Metabolism
- Cancer Diagnosis and Treatment
University Hospital of Zurich
2019-2025
University of Zurich
2020-2024
Heinrich Heine University Düsseldorf
2012-2023
Düsseldorf University Hospital
2012-2023
Klinik und Poliklinik für Urologie
2013-2016
Universitätskinderklinik
2010
University Children's Hospital Zurich
2010
SIS Medical (Switzerland)
2010
The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role in management metastatic germ cell tumors but relies on data patients treated between 1975 and 1990.Data 9,728 men with nonseminomatous cisplatin- etoposide-based first-line chemotherapy 1990 2013 were collected from 30 institutions or collaborative groups Europe, North America, Australia. Clinical trial registry included. Primary end points progression-free survival (PFS) overall (OS)....
The classification of the International Germ-Cell Cancer Collaborative Group (IGCCCG) has been a major advance in management germ-cell tumors, but relies on data only 660 patients with seminoma treated between 1975 and 1990. We re-evaluated this database from large international consortium.Data 2,451 men metastatic cisplatin- etoposide-based first-line chemotherapy 1990 2013 were collected 30 institutions or collaborative groups Australia, Europe, North America. Clinical trial registry...
While implanted port catheters ("PORTs") have historically been the standard device for intravenous systemic anticancer therapy, use of peripherally inserted central (PICCs) has increased continuously and reliable catheter selection guidelines are lacking. We compare complication rates PORTs PICCs in cancer treatment a retrospective study 3365 patients with both solid organ (n = 2612) hematologic 753) malignancies, between 2001 2021. 26.4% 890) all were treated via 73.6% (2475) PORTs. 20.7%...
Clinical stage I (CSI) nonseminoma (NS) is a disease limited to the testis without metastases. One treatment strategy after orchiectomy adjuvant chemotherapy. Little known about outcome of patients who experience relapse such treatment.Data from 51 with CSI NS experienced bleomycin, etoposide, and cisplatin (BEP) 18 centers/11 countries were collected retrospectively analyzed. Primary outcomes overall progression-free survivals calculated day 1 at first relapse. Secondary time to, at, rate...
Abstract Aims To investigate the level of adoption evidence‐based family engagement and support during end‐of‐life cancer care subsequent bereavement its contextual facilitators barriers from health professionals' perspectives, to explore differences between professional groups. Design Contextual analysis using an online cross‐sectional survey. Methods This study was conducted in four Swiss hospitals three home oncology palliative services. Non‐parametric testing used nurses, physicians,...
Abstract Background Losing a close other to cancer is an incisive experience that occurs after long course of illness and intense family caregiving. Despite evident need for engagement support guidance on this, patients members may not receive the attention they when unit experiencing disruption by death. A clear understanding quality care currently provided its ability address needs necessary improve end-of-life bereavement families affected cancer. The purpose this study investigate...
Abstract Purpose Mesothelioma of the tunica vaginalis testis (MTVT) is a rare tumor, and currently, there are no published treatment recommendations. Methods We performed systematic literature review synthesized clinical presentation, clinicopathological factors associated with metastatic disease, options, outcomes in men MTVT. Results included 170 publications providing data on 275 patients. Metastatic disease occurred 84/275 (31%) malignant MTVT: Most common sites retroperitoneal lymph...
There is ongoing controversy about the recommended dose of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).This multicenter phase II open-label, randomized, parallel-group study compared 3-weekly at 25 mg/m2 (conventional arm A) therapeutic drug monitoring (experimental B) mCRPC. The primary objective was to improve clinical feasibility rate (CFR), defined as absence grade 4 neutropenia or thrombocytopenia, any thrombocytopenia bleeding, febrile...
Patient preferences for treatment outcomes are important to guide decision-making in clinical practice, but little is known about the of patients with metastatic hormone-sensitive prostate cancer (mHSPC).To evaluate patient regarding attributed benefits and harms systemic treatments mHSPC preference heterogeneity between individuals specific subgroups.We conducted an online discrete choice experiment (DCE) survey among 77 (mPC) 311 men from general population Switzerland November 2021 August...
PurposeIn end-of-life cancer care, 10–20% of bereaved family members experience adverse mental health effects, including prolonged grief disorder. Despite great efforts, evidence-based recommendations to support their grieving process and well-being are often not successfully adopted into routine clinical care. This study identified facilitators barriers using implementation science methodology.Methods81 registered nurses working in care from four hospitals three home services Switzerland...
4518 Background: ctDNA is emerging as a potential biomarker of disease in early-stage bladder cancer but less understood advanced UC. We present retrospective analysis pre-treatment and on-treatment data by clinical outcomes with pembro monotherapy versus chemo pts UC from the phase 3 KEYNOTE-361 trial (NCT02853305). Methods: Pts previously untreated were randomly assigned 1:1:1 to + chemo, alone, or alone. Tumor tissue mutations evaluated whole exome sequencing tumor matched normal DNA....